Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, addresses whether biomarker testing is needed to ...

Lauren Banks, MD, PhD, discusses TIL therapy feasibility and safety in dedifferentiated liposarcoma and undifferentiated ...

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Five phase 3 analyses presented as late-breaking abstracts at the 2026 European Society for Medical Oncology (ESMO) Congress ...

Torvu-Sam is moving into phase 3 trials at a dose of 2 mg/kg. In PROC, it will be compared with mirvetuximab soravtansine in ...

A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...

The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or ...

Overall, Lorusso characterizes the TroFuse-005 findings as convincing, citing the magnitude of benefit across key clinical ...

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, ...

1. FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer ...